Anlotinib for Hepatocellular Carcinoma

Last updated: June 29, 2021
Sponsor: Guangxi Zhuang Autonomous Region People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Liver Cancer

Primary Biliary Cholangitis

Treatment

N/A

Clinical Study ID

NCT04954521
KY-QT-201905
  • All Genders

Study Summary

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age: ≥ 18 years old, male or female;
  2. Patients with advanced liver cancer were diagnosed;
  3. Patients assessed by doctors to benefit from single or combined treatment of arotinib;
  4. Patients volunteered to join the project.

Exclusion

Exclusion Criteria: None

Study Design

Total Participants: 200
Study Start date:
June 30, 2021
Estimated Completion Date:
July 05, 2024

Connect with a study center

  • People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi 530000
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.